Selected article for: "acute lung damage and lung tissue"

Author: Pillalamarri, Nagavalli; Abdullah; Ren, Gang; Khan, Luqman; Ullah, Asad; Jonnakuti, Sriya; Ullah, Mujib
Title: Exploring the utility of extracellular vesicles in ameliorating viral infection-associated inflammation, cytokine storm and tissue damage
  • Cord-id: hvaq7nzp
  • Document date: 2021_4_19
  • ID: hvaq7nzp
    Snippet: Extracellular vesicles (EVs) have emerged as potential mediators of intercellular communication. EVs are nano-sized, lipid membrane–bound vesicles that contains biological information in the form of proteins, metabolites and/or nucleic acids. EVs are key regulators of tissue repair mechanisms, such as in the context of lung injuries. Recent studies suggest that EVs have the ability to repair COVID19-associated acute lung damage. EVs hold great promise for therapeutic treatments, particularly i
    Document: Extracellular vesicles (EVs) have emerged as potential mediators of intercellular communication. EVs are nano-sized, lipid membrane–bound vesicles that contains biological information in the form of proteins, metabolites and/or nucleic acids. EVs are key regulators of tissue repair mechanisms, such as in the context of lung injuries. Recent studies suggest that EVs have the ability to repair COVID19-associated acute lung damage. EVs hold great promise for therapeutic treatments, particularly in treating a potentially fatal autoimmune response and attenuate inflammation. They are known to boost lung immunity and are involved in the pathogenesis of various lung diseases, including viral infection. EV-based immunization technology has been proven to elicit robust immune responses in many models of infectious disease, including COVID-19. The field of EV research has tremendous potential in advancing our understanding about viral infection pathogenesis, and can be translated into anti-viral therapeutic strategies.

    Search related documents:
    Co phrase search for related documents
    • activation antigen and lung injury: 1, 2
    • activator protein and lung disease: 1
    • activator protein and lung epithelial cell: 1
    • activator protein and lung fluid: 1
    • activator protein and lung injury: 1, 2, 3, 4, 5
    • activator protein and lung pathology: 1
    • lung injury and macrophage migration: 1, 2, 3, 4
    • lung injury and macrophage migration inhibitory factor: 1
    • lung injury and macular degeneration: 1, 2